India Digital Therapeutics Market Size, Share & Forecast, By Product Type, Disease Area & Care Setting, 2026–2031

The India Digital Therapeutics Market was valued at USD 253 million in 2025. The estimate covers revenue from evidence-based software interventions, connected therapeutic programs, clinical coaching, provider licences and enterprise-sponsored condition management while excluding general teleconsultation, electronic health records and non-therapeutic wellness content. Supply-side provider revenue, paid patient-equivalent volume and chronic disease demand were triangulated. Diabetes and metabolic programs represented the largest revenue pool, followed by behavioral health and cardiovascular care. The 2025 confidence range was USD 225-285 million, primarily reflecting private-company disclosure limitations and blurred boundaries between wellness and regulated DTx.

The market is forecast to grow at a 26.57% CAGR from the 2025 base and reach USD 1,040 million by 2031. Expansion will be driven by increasing paid enrollment, higher-value connected-care programs and migration toward provider, employer, insurer and pharmaceutical channels. Paid patient-equivalent volume is projected to rise from 1.15 million to 3.94 million, while average annual revenue per enrollee increases from USD 220 to USD 264. The forecast assumes greater clinical validation and enterprise adoption but does not assume universal insurance reimbursement or unrestricted medical-device approval.

The profit pool will shift from standalone direct-to-consumer subscriptions toward provider-prescribed, employer-sponsored and pharmaceutical or device-partnered programs. Institutional channels produce larger cohorts, longer contract duration and lower acquisition cost per patient, while connected devices and clinical oversight raise annual revenue per enrollee. Diabetes will remain the largest therapeutic category, but cardiac rehabilitation and post-discharge care may generate stronger unit economics because they address higher-risk patients and support episode-based pricing. AI-assisted coaching should improve gross margin where automated engagement is paired with selective clinician escalation.

The most important constraint is the gap between digital engagement and reimbursable, clinically accepted treatment. Many applications can attract users, but fewer demonstrate sustained adherence, statistically meaningful outcomes and compliance with medical-device and personal-data requirements. India's insurance architecture remains focused on hospitalization, while DTx frequently operates in preventive, outpatient and post-discharge settings. Patient attrition also weakens realized outcomes and revenue renewal. Operators therefore need disease-specific evidence, clear intended-use claims, clinician governance and transparent data practices rather than relying on broad wellness positioning.

India ranked second among the selected peer countries by estimated 2025 market value, behind China and ahead of Japan, South Korea and Australia. China remains larger because of greater current digital health expenditure and a similarly large chronic disease population. South Korea and Australia may grow faster from smaller bases, while Japan benefits from stronger reimbursement and pharmaceutical pathways. India's advantage is the combination of a large addressable patient population, deep software talent, lower-cost clinical support and rapidly expanding digital health infrastructure. Its principal weakness is less mature standardized reimbursement.

Diabetes and broader cardiometabolic risk have the greatest strategic impact because they combine a large patient population, measurable biomarkers and recurring behavioral intervention. India had approximately 89.8 million adults with diabetes in 2024, while the National NCD Portal recorded 8.64 crore people under treatment for hypertension and diabetes in 2025. These conditions support connected glucose monitoring, nutrition guidance, activity coaching, medication adherence and physician escalation. They also create clear buyer propositions for employers, insurers, pharmaceutical companies, hospitals and diagnostics providers.

Leading companies will combine clinical evidence, regulatory discipline, personalized intervention, connected monitoring, vernacular engagement and institutional distribution. Technology alone will not be sufficient: providers must demonstrate active engagement, clinical improvement and financial value to hospitals, employers or payers. ABDM-compatible interoperability will become increasingly important for longitudinal records and clinician workflow integration. Operators also need differentiated escalation models that reserve expensive human support for high-risk patients while using AI for routine education, reminders and behavioral reinforcement. Partnerships with pharmaceutical and medical-device companies can accelerate access but require clear ownership of data and outcomes.